127 related articles for article (PubMed ID: 16126281)
21. Polarized subsets of human T-helper cells induce distinct patterns of chemokine production by normal and systemic sclerosis dermal fibroblasts.
Chizzolini C; Parel Y; Scheja A; Dayer JM
Arthritis Res Ther; 2006; 8(1):R10. PubMed ID: 16356198
[TBL] [Abstract][Full Text] [Related]
22. Interferon-beta: mechanism of action and dosing issues.
Markowitz CE
Neurology; 2007 Jun; 68(24 Suppl 4):S8-11. PubMed ID: 17562848
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of chemokines in the skin of chronic proliferative dermatitis mutant mice.
Renninger ML; Seymour R; Lillard JW; Sundberg JP; HogenEsch H
Exp Dermatol; 2005 Dec; 14(12):906-13. PubMed ID: 16274458
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of action of IFN-beta in the treatment of multiple sclerosis: a special reference to CD73 and adenosine.
Airas L; Niemelä J; Yegutkin G; Jalkanen S
Ann N Y Acad Sci; 2007 Sep; 1110():641-8. PubMed ID: 17911479
[TBL] [Abstract][Full Text] [Related]
25. Interferon-beta therapy for multiple sclerosis--is the injection site the relevant action site?
Smith D
J Neuroimmunol; 2009 Oct; 215(1-2):117-21. PubMed ID: 19773087
[TBL] [Abstract][Full Text] [Related]
26. Interferon-beta therapy up-regulates BDNF secretion from PBMCs of MS patients through a CD40-dependent mechanism.
Azoulay D; Mausner-Fainberg K; Urshansky N; Fahoum F; Karni A
J Neuroimmunol; 2009 Jun; 211(1-2):114-9. PubMed ID: 19419774
[TBL] [Abstract][Full Text] [Related]
27. Innate immunity modulates autoimmunity: type 1 interferon-beta treatment in multiple sclerosis promotes growth and function of regulatory invariant natural killer T cells through dendritic cell maturation.
Gigli G; Caielli S; Cutuli D; Falcone M
Immunology; 2007 Nov; 122(3):409-17. PubMed ID: 17617156
[TBL] [Abstract][Full Text] [Related]
28. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: Relationships to 5-year clinical outcomes in multiple sclerosis patients.
Weinstock-Guttman B; Bhasi K; Badgett D; Tamaño-Blanco M; Minhas M; Feichter J; Patrick K; Munschauer F; Bakshi R; Ramanathan M
J Neuroimmunol; 2008 Dec; 205(1-2):113-25. PubMed ID: 18950872
[TBL] [Abstract][Full Text] [Related]
29. Expression and regulation of IFNalpha/beta receptor in IFNbeta-treated patients with multiple sclerosis.
Gilli F; Valentino P; Caldano M; Granieri L; Capobianco M; Malucchi S; Sala A; Marnetto F; Bertolotto A
Neurology; 2008 Dec; 71(24):1940-7. PubMed ID: 18971450
[TBL] [Abstract][Full Text] [Related]
30. Recurrent injection site reactions from interferon beta 1-b.
Samuel L; Lowenstein EJ
J Drugs Dermatol; 2006 Apr; 5(4):366-7. PubMed ID: 16673806
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
[TBL] [Abstract][Full Text] [Related]
32. Chemokine expression in human erythroid leukemia cell line AS-E2: macrophage inflammatory protein-3alpha/CCL20 is induced by inflammatory cytokines.
Inoue Y; Tsushima H; Ando K; Sawayama Y; Sakai M; Yamasaki R; Matsuo E; Tsutsumi C; Imaizumi Y; Iwanaga M; Imanishi D; Taguchi J; Miyazaki Y; Tomonaga M
Exp Hematol; 2006 Jan; 34(1):19-26. PubMed ID: 16413387
[TBL] [Abstract][Full Text] [Related]
33. [Skin reactions to interferon alpha in a series of 92 patients with multiple sclerosis].
Fortuño Y; Marcoval J; Gallego I; Moreno A; Arbizu T; Peyrí J
Med Clin (Barc); 1999 Oct; 113(12):447-8. PubMed ID: 10570511
[TBL] [Abstract][Full Text] [Related]
34. Skin reactivity and local cell recruitment in human atopic and nonatopic subjects by CCL2/MCP-1 and CCL3/MIP-1alpha.
Gaga M; Ong YE; Benyahia F; Aizen M; Barkans J; Kay AB
Allergy; 2008 Jun; 63(6):703-11. PubMed ID: 18070228
[TBL] [Abstract][Full Text] [Related]
35. Biologic role of interferon beta in multiple sclerosis.
Billiau A; Kieseier BC; Hartung HP
J Neurol; 2004 Jun; 251 Suppl 2():II10-4. PubMed ID: 15264107
[TBL] [Abstract][Full Text] [Related]
36. HLA class II and response to interferon-beta in multiple sclerosis.
Fernández O; Fernández V; Mayorga C; Guerrero M; León A; Tamayo JA; Alonso A; Romero F; Leyva L; Alonso A; Luque G; de Ramón E
Acta Neurol Scand; 2005 Dec; 112(6):391-4. PubMed ID: 16281922
[TBL] [Abstract][Full Text] [Related]
37. Cytokine and chemokine dynamics differ between rats and mice after collagen implantation.
Luttikhuizen DT; Harmsen MC; van Luyn MJ
J Tissue Eng Regen Med; 2007; 1(5):398-405. PubMed ID: 18038434
[TBL] [Abstract][Full Text] [Related]
38. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
Hamamcioglu K; Reder AT
Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
[TBL] [Abstract][Full Text] [Related]
39. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
[TBL] [Abstract][Full Text] [Related]
40. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
